Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) Research & Development (2016 - 2025)

Historic Research & Development for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $2.6 billion.

  • Bristol Myers Squibb's Research & Development fell 1895.96% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 billion, marking a year-over-year decrease of 1082.53%. This contributed to the annual value of $10.0 billion for FY2025, which is 1082.53% down from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Research & Development is $2.6 billion, which was down 1895.96% from $2.5 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Research & Development registered a high of $3.2 billion during Q4 2024, and its lowest value of $2.2 billion during Q1 2021.
  • For the 5-year period, Bristol Myers Squibb's Research & Development averaged around $2.5 billion, with its median value being $2.5 billion (2021).
  • As far as peak fluctuations go, Bristol Myers Squibb's Research & Development soared by 2877.32% in 2024, and later tumbled by 1895.96% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Research & Development (Quarter) stood at $2.5 billion in 2021, then dropped by 0.32% to $2.5 billion in 2022, then fell by 1.27% to $2.5 billion in 2023, then increased by 28.77% to $3.2 billion in 2024, then dropped by 18.96% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q4 2025, $2.5 billion for Q3 2025, and $2.6 billion during Q2 2025.